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Abstract
Background: The use of the point-of-care lateral flow lipoarabinomannan (LF-LAM) test may expedite tuberculosis
(TB) diagnosis in HIV-positive patients. However, the test’s clinical utility is poorly defined outside sub-Saharan Africa.
Methods: The study enrolled consecutive HIV-positive adults at a tertiary referral hospital in Yangon, Myanmar. On
enrolment, patients had a LF-LAM test performed according to the manufacturer’s instructions. Clinicians managing
the patients were unaware of the LF-LAM result, which was correlated with the patient’s clinical course over the
ensuing 6 months.
Results: The study enrolled 54 inpatients and 463 outpatients between July 1 and December 31, 2015. On enrolment,
the patients’ median (interquartile range) CD4 T-cell count was 270 (128–443) cells/mm3. The baseline LF-LAM test
was positive in 201/517 (39%). TB was confirmed microbiologically during follow-up in 54/517 (10%), with rifampicin
resistance present in 8/54 (15%). In the study’s resource-limited setting, extrapulmonary testing for TB was not possible,
but after 6 months, 97/201 (48%) with a positive LF-LAM test on enrolment had neither died, required hospitalisation,
received a TB diagnosis or received empirical anti-TB therapy, suggesting a high rate of false-positive results.
Of the 97 false-positive tests, 89 (92%) were grade 1 positive, suggesting poor test specificity using this cut-off. Only
21/517 (4%) patients were inpatients with TB symptoms and a CD4 T-cell count of < 100 cells/mm3. Five (24%) of these
21 died, three of whom had a positive LF-LAM test on enrolment. However, all three received anti-TB therapy before
death — two after diagnosis with Xpert MTB/RIF testing, while the other received empirical treatment. It is unlikely that
knowledge of the baseline LF-LAM result would have averted any of the study’s other 11 deaths; eight had a negative
test, and of the three patients with a positive test, two received anti-TB therapy before death, while one died from
laboratory-confirmed cryptococcal meningitis. The test was no better than a simple, clinical history excluding TB during
follow-up (negative predictive value (95% confidence interval): 94% (91–97) vs. 94% (91–96)).
Conclusions: The LF-LAM test had limited clinical utility in the management of HIV-positive patients in this Asian
referral hospital setting.
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Background
Tuberculosis (TB) is the most common cause of death
in HIV-infected patients globally [1, 2]. Limited access
to laboratory services in low- and middle-income coun-
tries means that almost half the fatal cases of TB/HIV
co-infection are unrecognised before the patients die [1, 3].
Even where there is access to laboratory services, there
are significant challenges in diagnosing TB in HIV-
positive patients [4]; mycobacterial culture is resource-
intensive and may take weeks to provide results, sputum
microscopy is rapid and inexpensive but has a sensitivity
of less than 50% in HIV-positive patients [5], and while
the Xpert MTB/RIF assay is endorsed by the World
Health Organization (WHO), its use has not been shown
to improve mortality [6–8].
Against this background, the development of the
point-of-care urine-based lateral flow lipoarabinoman-
nan (LF-LAM) test has been hailed as a significant
advance [9]. The test requires no laboratory infra-
structure, is cheaper and simpler to perform than the
Xpert MTB/RIF assay, and lacks the infection risks
associated with sputum collection [10]. The test has
shown greatest utility in facilitating the diagnosis of
TB in HIV-positive hospital inpatients with advanced
immunodeficiency and symptoms of TB, the popula-
tion at greatest risk of death [4, 11]. In sub-Saharan
Africa, the use of LF-LAM testing to diagnose TB
proved cost-effective [12, 13] and reduced 8-week
mortality in HIV-positive hospital inpatients [14].
More data are required to support the use of the test
in outpatients, although extrapolating from the find-
ings in inpatients, it has been suggested that it may
have a role in seriously ill outpatients with more
advanced immunodeficiency [10].
The utility of LF-LAM in excluding the diagnosis of
TB in HIV-positive patients is incompletely defined, al-
though the expert consensus in current WHO recom-
mendations is that the test should not be used for this
purpose [10]. The test’s relatively high negative predict-
ive value (NPV) might be hypothesised to assist in
excluding TB before isoniazid prophylaxis therapy
(IPT) or antiretroviral therapy (ART) is initiated, but
the safety of this approach has not been established.
It is also not clear that using the test to exclude TB
is better than a simple clinical history, which also has
an excellent NPV [15].
Importantly, most of the research to define the clinical
utility of the LF-LAM test has been performed in sub-
Saharan Africa, the region with the world’s highest rates
of HIV/TB co-infection. By contrast, relatively few data
have been collected in Asia [2, 16–18]. This is significant
as the performance of a diagnostic test depends on the
local prevalence of the condition, and effective manage-
ment strategies based on the performance of a
diagnostic test in one location are not necessarily gener-
alisable to other populations [19].
Furthermore, the LF-LAM test itself has evolved over
time [20]. When the faintest bands in an earlier version
were used to define a positive result (grade 1 cut-off ) as
recommended by the manufacturer, the test’s specificity
in culture-negative patients was poor (66%, 95% confi-
dence interval (CI), 57–74); however, this improved to
96% (95% CI, 89–100) when the more intense grade 2
cut-off was used [21]. To simplify the test’s interpret-
ation, in January 2014, the manufacturer revised the ref-
erence card that ‘scores’ the test to have only four bands;
the band intensity for a grade 1 positive test on the new
reference card corresponding to the band intensity of
the previous grade 2 positive test. However, the perform-
ance of this revised version of the test requires validation
[4].
Therefore, this study was performed to evaluate the
clinical utility of the LF-LAM test in a cohort of HIV-
positive patients in Myanmar. It was hypothesised that
the test result would correlate well with the patients’
subsequent clinical course, providing justification for its
employment in diagnostic and management strategies to
reduce mortality in HIV-positive patients in Southeast
Asian countries.
Methods
This observational study was performed at Insein
General Hospital, a tertiary referral hospital in Yangon,
Myanmar’s largest city. All HIV-positive inpatients and
outpatients (whether seeking care for symptoms or in
routine follow-up) were eligible for inclusion. Patients
were enrolled consecutively between July 1, 2015, and
December 31, 2015 (Fig. 1). A 6-month period was
chosen to assess the everyday applicability of the LF-
LAM test in this high caseload hospital.
After obtaining informed consent, study doctors —
who were not involved in the patient’s routine care —
collected a detailed medical history using a dedicated
pro forma, performed a physical examination and re-
corded available laboratory data. Patients were defined
as having symptoms suggestive of TB if they had experi-
enced any cough, fever, night sweats or weight loss in
the previous month. A chest X-ray was ordered and spu-
tum was collected for culture (Lowenstein Jensen
medium) and Xpert MTB/RIF testing in all patients. If
the patient could not produce sputum spontaneously, it
was induced using hypertonic saline with appropriate
precautions. A separate study doctor, blinded to the clin-
ical details of the case, then collected urine in all
patients and performed the LF-LAM test (Alere
Determine™ TB LAM Ag) according to the manufac-
turer’s instructions. Positive tests were graded ac-
cording to the manufacturer’s new reference card
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(grade 1, 2, 3 or 4). For the test result to be scored
as grade 1, the band on the test-strip had to be at
least as intense as the corresponding grade 1 band
on the reference card, but not as intense as the
grade 2 band. If the study doctor was uncertain of
the LF-LAM result, a consensus was reached with
another study doctor and one of the authors (SST),
both of whom were also unaware of the patient’s
clinical presentation. To further reduce the risk of
bias, digital photographs were taken of the LF-LAM
tests at the time of testing. Another author (JH), un-
aware of the patient’s clinical presentation, later ex-
amined these photographs to grade the tests
independently.
The patient’s usual medical team continued the pa-
tient’s care without knowledge of the LF-LAM test re-
sult, as the test was not approved for use in
Myanmar at the time the study was undertaken. This
care included the initiation of empirical TB therapy if
this was felt to be clinically indicated. The patients’
clinical course was followed prospectively by the
study doctors for 6 months after enrolment. The pa-
tients were defined as having confirmed TB if they
returned either a positive culture for Mycobacterium
tuberculosis or a positive Xpert MTB/RIF assay in the
ensuing 6 months. Patients were defined as having a
complicated course if they had a confirmed TB diag-
nosis, received empirical anti-TB therapy, required
hospitalisation or died during the study.
Extrapulmonary samples were not collected, as
facilities to process these samples were not available
in Myanmar’s public health system at the time of the
study. However, it was reasoned that, after 6 months
of follow-up, if a patient had not had a confirmed
TB diagnosis and had not died, required hospitalisa-
tion or received empirical anti-TB therapy, a positive
baseline LF-LAM test was likely to be a false-positive
test.
Statistical analysis
All data were de-identified and entered into an elec-
tronic database (Microsoft Excel). Statistical analysis
was performed using statistical software (Stata).
Groups were analysed using the Kruskal–Wallis test
and the χ2 test. Inter-rater reliability was tested using
Cohen’s kappa. The LF-LAM test’s performance was
evaluated using the original test results reported by




The study enrolled 517 consecutive patients (Fig. 1),
463 (89.6%) inpatients (Fig. 2) and 54 (10.4%)
outpatients (Fig. 3). The patients’ median age was 34
(interquartile range (IQR), 30–41) years; 259 (50.1%)
were male and 258 (49.9%) were female. The median
(IQR) CD4 T-cell count on enrolment was 270
(128–443) cells/mm3; 360/517 (70%) patients were
receiving ART and 14/517 (3%) were receiving IPT.
The patients’ other characteristics are presented in
Table 1.
Clinical course
No patient was lost to follow-up (Fig. 1). After
6 months, 54/517 (10%) had a confirmed TB diagno-
sis including eight (15%) with rifampicin resistance on
Xpert MTB/RIF testing. All 54 patients with a con-
firmed TB diagnosis received anti-TB therapy; 123
(27%) of the remaining 463 patients received empir-
ical anti-TB therapy during the study in the absence
of a confirmed TB diagnosis. Sixteen (3%) of the 517
Fig. 1 Study profile. No patients were lost to follow-up during the study period
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patients died during the study — 6/54 (11%) enrolled
as inpatients and 10/463 (2%) enrolled as outpatients.
Only 4/54 (7%) inpatients and 2/463 (0.4%) outpa-
tients died within 8 weeks of enrolment. Of the 463
enrolled as outpatients, 23 (5%) were hospitalised dur-
ing follow-up.
LF-LAM test results and inter-rater reliability
All 517 patients had a LF-LAM test performed on enrol-
ment — 201 (39%) had a positive test (≥ grade 1), 43
(8.3%) had ≥ grade 2 positive test and 20 (3.9%) had a ≥
grade 3 positive test. The photograph of the LF-LAM
test could be read with confidence in 503/517 (97%).
Fig. 2 Clinical course of patients enrolled as inpatients. aOne case of TB meningitis, one case of miliary TB. bOne case of suspected TB meningitis.
cOne case of microbiologically confirmed cryptococcal meningitis. dTwo cases of suspected Pneumocystis jirovecii pneumonia
Fig. 3 Clinical course of patients enrolled as outpatients. aOne case of suspected miliary TB, one case of suspected TB meningitis. bOne case of
confirmed TB meningitis (rifampicin resistant on Xpert MTB/RIF assay). cTwo cases of suspected TB meningitis, one case of suspected
miliary TB, one case of suspected toxoplasmosis, one case of HIV cachexia. dOne case of confirmed cryptococcal meningitis, one case of
suspected toxoplasmosis
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The qualitative result was the same as the initial assess-
ment in 459/503 (91%, kappa coefficient 0.82) using a
grade 1 cut-off to define a positive test.
Characteristics of patients with a positive LF-LAM test
The patients with a positive LF-LAM test were more
likely to be inpatients at enrolment (P < 0.001) or have















Age, years 34 (30–41) 34 (30–41) 34 (29–41) 34 (28–42) 34 (28–45)
Male sex 259 (50%) 158 (50%) 101 (50%) 22 (51%) 9 (45%)
Enrolled as inpatient 54 (10%) 19 (6%) 35 (17%)*** 15 (35%)*** 10 (50%)***
Symptoms of systemic TB a 169 (33%) 90 (29%) 79 (39%)* 32 (74%)*** 16 (80%)***
Cough in last month 116 (22%) 56 (18%) 60 (30%)*** 23 (53%)*** 12 (60%)***
Current cigarette smoker 150 (29%) 88 (28%) 62 (31%) 16 (37%) 8 (40%)
Current tobacco chewing 222 (43%) 133 (42%) 89 (44%) 23 (53%) 11 (55%)
Hazardous alcohol consumption 71 (14%) 31 (10%) 40 (20%)*** 13 (30%)*** 6 (30%)*
Body mass index 20.8 (18.8–23.1) 21.2 (19.3–23.5) 20.4 (18.6–22.7)* 19.5 (17.8–22.0)** 19.4 (17.6–22.0)
Recent subjective weight loss 235 (45%) 135 (43%) 100 (50%) 30 (70%)*** 15 (75%)**
Abnormal respiratory examination 28 (5%) 8 (3%) 20 (10%)*** 11 (26%)*** 6 (30%)***
On anti-retroviral therapy 360 (70%) 225 (71%) 135 (67%) 24 (56%)* 9 (45%)*
On isoniazid prophylaxis therapy 14 (3%) 9 (3%) 5 (2%) 1 (2%) 0
CD4 T-cell count, cells/mm3 b 270 (128–443) 289 (151–481) 233 (95–409)* 112 (55–264)*** 71 (31–159)***
Haemoglobin, g/dLb 10.5 (9.2–12.2) 10.7 (9.4–12.1) 10.1 (9.0–12.0) 9.1 (8.1–10.2)*** 8.6 (6.5–10.1)***
White cell count, × 109/Lb 6.9 (5.3–8.7) 6.9 (5.4–8.6) 6.9 (5.3–8.9) 6.3 (5.4–10.5) 6.1 (4.5–6.2)
Lymphocytes, × 109/Lb 1.7 (1.2–2.5) 1.8 (1.3–2.5) 1.7 (1.1–2.4) 1.3 (0.5–2.2)** 0.8 (0.4–1.6)***
Platelets, × 109/Lb 291 (225–357) 288 (219–348) 295 (239–375) 277 (224–330) 276 (216–332)
Creatinine, μmol/Lb 85 (72–98) 85 (72–97) 86 (73–98) 80 (74–98) 84 (68–114)
Total bilirubin, μmol/Lb 13.2 (7.8–17.1) 12.6 (7.8–17.3) 13.5 (7.8–16.9) 15.0 (6.7–16.9) 12.5 (5.5–16.2)
Abnormal chest X-rayb 186 (38%) 102/294 (35%) 84/190 (44%)* 17/40 (43%) 9/18 (50%)
Gross abnormality on chest X-rayb 57 (12%) 29/294 (10%) 28/190 (15%) 8/40 (20%) 3/18 (17%)
TB diagnosis at 1 months 37 (7%) 10 (3%) 27 (13%)*** 14 (33%)*** 8 (40%)***
TB diagnosis at 3 months 44 (9%) 12 (4%) 32 (16%)*** 16 (37%)*** 8 (40%)***
TB diagnosis at 6 months 54 (10%) 18 (6%) 36 (18%)*** 17 (40%)*** 9 (45%)***
Empirical TB therapy at 1 monthc 33 (7%) 17 (6%) 16 (9%) 5 (17%)* 1 (8%)
Empirical TB therapy at 3 monthsc 84 (18%) 45 (15%) 39 (23%)* 11 (41%)*** 6 (50%)**
Empirical TB therapy at 6 monthsc 123 (27%) 71 (24%) 52 (32%) 13 (50%)** 6 (55%)*
Dead at 1 month 5 (1%) 3 (1%) 2 (1%) 2 (5%)* 1 (5%)
Dead at 3 months 13 (3%) 7 (2%) 6 (3%) 5 (12%)*** 4 (20%)***
Dead at 6 months 16 (3%) 10 (3%) 6 (3%) 5 (12%)*** 4 (20%)***
Complicated coursed 205 (40%) 101 (32%) 104 (52%)*** 35 (81%)*** 18 (90%)***
False-positive LF-LAM teste 97 (19%) – 97 (48%) 8 (19%) 2 (10%)
All values represent absolute number (%), or median (interquartile range)
* P < 0.05, ** P <0.01, *** P ≤ 0.001 (comparisons using Kruskal–Wallis and χ2 tests at the different cut-offs)
aCough, fever, weight loss or night sweats in last month
bOne patient did not have a CD4 count recorded at enrolment; 103 (20%) patients did not have an available haemoglobin; 107 (21%) did not have an available
white blood cell count; 110 (21%) did not have an available lymphocyte count; 111 (21%) did not have an available creatinine; 143 (28%) did not have an
available platelet count; 33 (6%) patients did not have an available chest-X-ray report
cDoes not include the patients prescribed anti-TB therapy for a microbiologically confirmed diagnosis
dComplicated course: death, hospitalisation, confirmed TB diagnosis or initiation of empirical anti-TB therapy in the 6 months of follow-up
ePositive LF-LAM test on enrolment, but no death, hospitalisation, confirmed TB diagnosis or initiation of empirical anti-TB therapy in the 6 months of follow-up
LF-LAM lateral flow lipoarabinomannan, TB tuberculosis
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TB symptoms (P = 0.01). They were more likely to have
advanced immunodeficiency (CD4 T-cell count < 100
cells/mm3) (P = 0.003), a history of hazardous alcohol
use (P < 0.001), a body mass index < 18 kg/m2 (P = 0.03)
or a haemoglobin level < 10 g/dL (P = 0.02) (Table 1).
Correlation between a positive LF-LAM test result and the
subsequent clinical course
Patients with a positive LF-LAM test were more likely to
have a confirmed TB diagnosis during follow-up than
patients with a negative test (36/201 (18%) vs. 18/316
(6%), P < 0.001) and were more likely to have a compli-
cated course (104/201 (52%) vs. 101/316 (32%), P <
0.001) (Table 1, Additional file 1: Table S1 and Add-
itional file 2: Table S2). The 43/517 (8.3%) patients with
a more strongly positive test (≥ grade 2) were more
likely than patients with a negative or grade 1 result to
have a confirmed TB diagnosis during follow-up (17/43
(40%) vs. 37/474 (8%), P < 0.001) and to have a compli-
cated course (35/43 (81%) vs. 170/474 (36%), P < 0.001).
There were 97/517 (19%) patients in the entire cohort
with a false-positive LF-LAM test. Of these 97 patients,
89 (92%) had a grade 1 positive test (Table 1).
Correlation between a negative LF-LAM test result and
the subsequent clinical course
Patients with a negative LF-LAM test were less likely to
have a confirmed TB diagnosis (NPV (95% CI), 94%
(91–97)) or complicated course in the ensuing 6 months
(NPV (95% CI), 68% (63–73)). However, the absence of
TB symptoms on clinical history had a similar ability to
exclude both endpoints (NPV (95% CI), 94% (91–96) for
a confirmed TB diagnosis and 71% (66–76) for a compli-
cated course, respectively).
Utility of the LF-LAM test in symptomatic inpatients
There were 41 (7.9%) inpatients in the cohort with
symptoms of TB on enrolment (median CD4 T-cell
count (IQR), 96 (37–277) cells/mm3) (Fig. 4). These
patients were less likely to be receiving ART than the
rest of the cohort (13/41 (32%) vs. 347/476 (73%), P <
0.001). Six (15%) of these 41 patients died; four had a
positive LF-LAM test, three of whom received anti-TB
therapy prior to death. Two of these three had TB
diagnosed with Xpert on sputum, while the third had
empirical anti-TB therapy for presumed TB meningitis.
The one patient with a positive LF-LAM test who re-
ceived no anti-TB therapy prior to death, died from
laboratory-confirmed (India Ink positive) cryptococcal
meningitis (Table 2). The LF-LAM test’s PPV in these
41 patients for either death, confirmed TB or empirical
anti-TB therapy in the subsequent 6 months was 63%
(95% CI, 42–81).
Only 21/517 (4.1%) were inpatients with TB symptoms
and a CD4 T-cell count of < 100 cells/mm3. These pa-
tients were less likely to be receiving ART than the rest
of the cohort (7/21 (33%) vs. 353/496 (71%), P < 0.001).
Five (24%) of the 21 patients died; three of whom had a
positive LF-LAM test, but all received anti-TB therapy
prior to death. Two of the three had TB diagnosed with
Xpert on sputum, while the third had empirical anti-TB
treatment for presumed TB meningitis (Table 2). The
LF-LAM test’s PPV in these 21 patients for either death,
confirmed TB or empirical anti-TB therapy in the subse-
quent 6 months was 83% (95% CI, 52–98).
Ability of the LF-LAM test to avert mortality
Of the 16 deaths in the study, six occurred in inpatients
and are described above. The other ten occurred in out-
patients, eight of whom had a negative LF-LAM test.
The remaining two patients both received empirical
anti-TB therapy prior to death (Table 2).
Discussion
In this observational study of consecutively enrolled
HIV-positive Southeast Asian patients at a tertiary
Fig. 4 Ability of the LF-LAM test to predict important clinical endpoints in inpatients with TB symptoms. aIncludes the 6 patients with confirmed
TB and 10 patients who had empirical anti-TB therapy started. bAll 7 patients had empirical anti-TB therapy started. PPV positive predictive value,
NPV negative predictive value, both presented as percentage (95% confidence interval)
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referral hospital, the LF-LAM test had limited clinical
utility. The test had poor specificity and would have
been unlikely to avert any deaths in the 6 months of the
study. The test is also unable to identify drug resistance,
which was present in almost 15% of the confirmed infec-
tions. In this Southeast Asian referral hospital setting at
least, the LF-LAM test appears to add little to existing
management strategies.
Most of the studies assessing the LF-LAM test have
focussed on its sensitivity and specificity in diagnosing
TB in HIV-positive patients in sub-Saharan Africa [4, 10].
However, the test’s PPV and NPV, which take into
account the local prevalence of the disease, have more
relevance to clinical decision-making [19]. The burdens
of HIV and TB in Myanmar are among the highest in
Southeast Asia: approximately 0.8% of adults in the coun-
try aged 18–49 are HIV-positive and TB kills an estimated
4800 HIV-positive patients annually [2, 22]. However, the
incidence of HIV-TB co-infection in Myanmar is approxi-
mately 15 times lower than in South Africa, where much
of the LF-LAM test’s validation has occurred [2, 23]. This
is important to remember when considering LF-LAM-
based diagnostic and management algorithms developed
in Africa for use in other regions, as the test’s PPV for TB
infection will necessarily be lower in countries with a
lower TB prevalence [19].
In this series, the PPV of the LF-LAM test was
poor — if clinicians had used the test to guide treat-
ment, many patients would have received anti-TB
therapy they did not require. For individual patients,
this unnecessary therapy would have increased the
risk of adverse effects and drug-drug interactions, and
may have influenced adherence to ART [24, 25]. At a
hospital level, there would have been the logistic and
financial challenges of delivering this additional ther-
apy [25]. While the test’s NPV was better, it was not
superior to a focussed history in excluding the diag-
nosis, replicating the findings in another Southeast
Asian cohort where a simple history was very helpful
in excluding active TB [15].
Table 2 Characteristics of the patients who died during follow-up
Age, Gender CD4 T-cell
counta
On ARTa On IPTa Initial
enrolment





23, Female 56 Yes No Inpatient Positive grade 3 Yes Empirical 3 days Suspected TB meningitis
32, Female 59 No No Inpatient Positive grade 2 Yes Directed 29 days Confirmed TB meningitis
28, Female 14 No No Inpatient Positive grade 3 Yes Directed 34 days Confirmed miliary TB
28, Female 144 Yes No Inpatient Positive grade 4 Yes No 87 days Confirmed cryptococcal
meningitis
33, Female 61 No No Inpatient Negative Yes No 131 days Suspected Pneumocystis
jirovecii pneumonia
26, Female 53 Yes No Inpatient Negative Yes No 3 days Suspected Pneumocystis
jirovecii pneumonia
48, Male 114 Yes No Outpatient Positive grade 1 No Empirical 63 days Suspected miliary TB
36, Male 54 Yes No Outpatient Positive grade 3 Yes Empirical 79 days Suspected TB meningitis
38, Female 121 Yes No Outpatient Negative No Empirical 72 days Suspected miliary TB
60, Female 96 No No Outpatient Negative No Empirical 169 days HIV related cachexia
(died at home)
39, Male 512 Yes No Outpatient Negative No Directed 69 days Confirmed TB meningitis
34, Male 495 Yes No Outpatient Negative No No 159 days Confirmed cryptococcal
meningitis
37, Male 39 Yes No Outpatient Negative No Empirical 83 days Suspected cerebral
toxoplasmosis
31, Male 46 Yes No Outpatient Negative Yes Empirical 82 days Suspected TB meningitis
35, Female 107 Yes No Outpatient Negative No No 27 days Suspected cerebral
toxoplasmosis
36, Male 80 No No Outpatient Negative Yes Empirical 26 days Suspected TB meningitis
aOn enrolment
bCough, fever, weight loss or night sweats in last month
cThree patients had directed therapy based on positive Xpert MTB/RIF assay on sputum
dDays after study enrolment
eLikely cause of death determined by attending clinician at time of death, unaware of LF-LAM result. Insufficient laboratory support to confirm diagnosis in most
cases. Confirmed TB based on positive Xpert MTB/RIF assay of sputum. Confirmed cryptococcal meningitis based on India ink of cerebrospinal fluid. Suspected
cerebral toxoplasmosis based on CT imaging results and clinical features. Suspected Pneumocystis jirovecii pneumonia based on clinical and radiological features
ART antiretroviral therapy, IPT isoniazid prophylaxis therapy LF-LAM lateral flow lipoarabinomannan, TB tuberculosis
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Meanwhile, few, if any, of the deaths in the study
would have been averted if the patients’ clinicians had
been aware of the LF-LAM result. Only six of the pa-
tients who died in the study had a positive LF-LAM test,
five of whom received anti-TB therapy before their
death. The one patient with a positive LF-LAM result,
who did not receive anti-TB therapy before death, died
of laboratory-confirmed cryptococcal meningitis almost
3 months after enrolment. Despite the cohort’s median
CD4 T-cell count of 270 cells/mm3, there were only six
deaths in the first 8 weeks of the study, two of which
occurred in outpatients. The low mortality rates seen in
this study are similar to those seen from other studies
performed in HIV-positive patients in Myanmar [26–28]
and much lower than those seen in locations where
the LF-LAM-based management algorithms have a
mortality benefit [14].
WHO recommendations suggest that the LF-LAM test
has greatest utility in hospital inpatients with signs and
symptoms of TB and advanced immunodeficiency (CD4
T-cell count < 100 cells/mm3) [4]. Certainly, the test’s
PPV for both a confirmed TB diagnosis and a compli-
cated clinical course was greater in this group in this
study (Additional file 1: Table S1 and Additional file 2:
Table S2). However, the pre-test probability of a TB diag-
nosis in the ensuing 6 months in this population is
already so high that any diagnostic test must have an ex-
cellent performance to affect the post-test probability
and influence clinical management; unfortunately, in this
series, that was not the case.
The poor specificity of the LF-LAM test in this cohort
is quite different to the excellent specificity reported in
some South African series with older versions of the test
[4, 29]. However, we used the test according to the man-
ufacturer’s instructions and we used the manufacturer’s
reference card to define all positive tests. Independent
review of photographs of the test strips excluded the
possibility of significant test misinterpretation. The fact
that over 90% of the false-positive tests were grade 1
positive results suggests a problem with using this cut-
off to define a positive test. However, if the cut-off were
raised to grade 2, the test’s sensitivity would fall and the
false-positive rate would still be a concerning 19%.
It is unclear whether the poor specificity seen in this
series is an issue with the test itself, the batch of tests
that were used in this study, or the study doctors’ ability
to read the tests. Even with the reference card, the fact
that a consensus was sometimes required to interpret
the test highlights some of the issues with its use in
guiding clinical management and is reminiscent of the
poor interobserver agreement when the faintest band
was used to define a positive result in the older version
of the test [21]. Cross-reactivity with non-tuberculous
mycobacteria, including M. kansasii, M. avium and M.
fortuitum, has also been proposed as an explanation for
reduced specificity in different locations, and the preva-
lence of these organisms has substantial geographic vari-
ation [20, 30, 31].
Whatever the explanation for the disappointing results,
they suggest that this novel diagnostic test is unlikely to
have a major impact on TB-related mortality in HIV-
positive patients in Myanmar. Meanwhile, established
interventions that unequivocally reduce TB-related mor-
tality remain poorly implemented in the country [28, 32].
There has been a significant recent increase in ART pre-
scription in Myanmar [33]; however, even at this teaching
hospital in the country’s largest city, almost one third of
patients were not receiving ART at enrolment. Addition-
ally, less than 3% of the patients in this cohort were receiv-
ing IPT despite its proven efficacy and recommendation
in WHO guidelines [34–36].
Our results require validation. However, even if
other studies in Asia showed the LF-LAM test to be
more reliable, it is likely to have very limited everyday
applicability in Myanmar [37]. The study took place
at a high caseload referral hospital, but only 4% of
the consecutively enrolled cohort were inpatients with
symptoms of TB and advanced immunodeficiency, the
population in whom the test is most helpful. With
improving ART coverage in the country, the number
of patients with advanced immunodeficiency is expected
to fall, further reducing the test’s utility. Another under-
reported limitation of the LF-LAM test is its inability
to assist in the diagnosis of drug-resistant TB, present
in 15% of this series and a significant and growing
issue in Myanmar [2]. In any patient with a positive
LF-LAM test, exclusion of drug-resistant TB would
require supplementary testing.
The study’s interpretation is complicated by the fre-
quent prescription of empirical anti-TB therapy [38].
However, while empirical anti-TB therapy has many lim-
itations, in the absence of reliable diagnostic testing, its
judicious administration in high-risk patients may some-
times be justified [25, 39]. Indeed, in a country where
TB is the most common cause of death in HIV-positive
patients, the mortality rate was low compared to other
series from similar settings [40–43]. This does not
necessarily suggest that empirical anti-TB therapy should
be prescribed at the inflated rate seen here. However,
the risk–benefit ratio of such a strategy can be optimised
by targeting the patients at highest risk of disease and
death, such as those with advanced immunodeficiency
[44], while excluding patients at lower risk of disease
such as those with recent treatment [45] or those with
co-morbidities that might be exacerbated by drug tox-
icity [25]. Hopefully, future improvements in diagnostic
testing for TB will eventually obviate the need for this
relatively crude therapeutic approach.
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The main limitation of the study is the fact that
only sputum specimens were collected in the pa-
tients, a low-quality reference standard when extra-
pulmonary TB is common in HIV-positive patients
[4]. Performing simultaneous mycobacterial culture of
blood, urine and tissue specimens would have un-
doubtedly increased the number of confirmed TB
diagnoses, but this requires substantial laboratory
capacity that is not available in the public health
systems of Myanmar and other Southeast Asian low-
and middle-income countries. However, notwith-
standing this fact, every patient was followed for
6 months after enrolment, permitting complete docu-
mentation of the important clinical endpoints of
death, hospitalisation and the prescription of anti-TB
therapy, and there were no patients lost to follow-up,
a significant strength of the study. While the refer-
ence standard was imperfect, if a patient was alive
without hospitalisation or receipt of anti-TB therapy
in the 6 months of follow-up, it is reasonable to as-
sume that the positive LF-LAM tests at enrolment in
these patients were false positives. Indeed, our esti-
mation of the false-positive rate is likely to be con-
servative as it is almost certainly the case that not all
patients who were hospitalised or who received
empirical anti-TB therapy had active TB.
Conclusions
In this Southeast Asian tertiary referral hospital set-
ting, the LF-LAM test generated a large number of
false-positive tests, which, if used to guide therapy,
would have resulted in many patients receiving un-
necessary treatment. Although the test’s NPV was bet-
ter, it was not superior to a simple, clinical history.
Knowledge of the LF-LAM test result would have
been unlikely to avert any of the deaths in the study
and would not have recognised the significant number
of drug-resistant cases. Even in the target population
of inpatients with TB symptoms, a relatively small
proportion of patients in even this high caseload hos-
pital, the test had limited practical and clinical utility.
Meanwhile, almost a third of patients at this tertiary
referral hospital were not receiving ART at enrolment
and 97% were not receiving IPT. While future studies
may demonstrate that the LF-LAM test has utility in
more nuanced, geographically specific, diagnostic
algorithms, particularly in inpatients with advanced
immunodeficiency, as a stand-alone test in this study,
it added little to existing everyday diagnostic and
management strategies. In the Southeast Asian set-
ting, overcoming barriers to the rollout of ART and
uptake of IPT are likely to have a far greater impact
on reducing TB-related morbidity and mortality.
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